Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

The prevalence of antiretroviral drug resistance in the United States.

Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA.

AIDS. 2004 Jul 2;18(10):1393-401.

PMID:
15199315
2.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
3.

Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.

Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, Moore RD, Bates M, Quinn TC.

Clin Infect Dis. 2006 Jan 15;42(2):252-9. Epub 2005 Dec 12.

4.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
5.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
6.

Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.

Di Giambenedetto S, Bracciale L, Colafigli M, Cattani P, Pinnetti C, Bacarelli A, Prosperi M, Fadda G, Cauda R, De Luca A.

Antivir Ther. 2007;12(5):835-9. Erratum in: Antivir Ther. 2007;12(7):1145. Colatigli, Manuela [corrected to Colafigli, Manuela; Cattani, Paola [added]; Pannetti, Carmen [corrected to Pinnetti, Carmen].

PMID:
17713168
7.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

8.

Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.

Recsky MA, Brumme ZL, Chan KJ, Wynhoven B, Yip B, Dong WW, Heath KV, Montaner JS, Levy AR, Hogg RS, Harrigan PR.

J Infect Dis. 2004 Jul 15;190(2):285-92. Epub 2004 Jun 11.

9.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].

Panel de expertos de GESIDA; Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2007 Jan;25(1):32-53. Spanish.

PMID:
17261244
10.

A genotyping study of human immunodeficiency virus type-1 drug resistance in a small Brazilian municipality.

Eyer-Silva WA, Morgado MG.

Mem Inst Oswaldo Cruz. 2005 Dec;100(8):869-73. Epub 2006 Jan 20.

11.

[Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].

Oette M, Kaiser R, Däumer M, Fätkenheuer G, Rockstroh JK, Knechten H, Mitrenga D, Beerenwinkel N, Sagir A, Pfister H, Häussinger D.

Dtsch Med Wochenschr. 2007 May 4;132(18):977-82. German.

PMID:
17457780
12.

Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies.

Wohl DA, Zeng D, Stewart P, Glomb N, Alcorn T, Jones S, Handy J, Fiscus S, Weinberg A, Gowda D, van der Horst C.

J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):538-44.

PMID:
15793363
13.

Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.

Oette M, Kaiser R, Däumer M, Akbari D, Fätkenheuer G, Rockstroh JK, Stechel J, Rieke A, Mauss S, Schmalöer D, Göbels K, Vogt C, Wettstein M, Häussinger D.

Eur J Med Res. 2004 May 28;9(5):273-8.

PMID:
15257882
14.

Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.

Delaugerre C, Warszawski J, Chaix ML, Veber F, Macassa E, Buseyne F, Rouzioux C, Blanche S.

J Med Virol. 2007 Sep;79(9):1261-9.

PMID:
17607781
15.

Infrequent transmission of HIV-1 drug-resistant variants.

Yerly S, Jost S, Telenti A, Flepp M, Kaiser L, Chave JP, Vernazza P, Battegay M, Furrer H, Chanzy B, Burgisser P, Rickenbach M, Gebhardt M, Bernard MC, Perneger T, Hirschel B, Perrin L; Swiss HIV Cohort Study.

Antivir Ther. 2004 Jun;9(3):375-84.

PMID:
15259900
16.

Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire.

Chaix ML, Rouet F, Kouakoussui KA, Laguide R, Fassinou P, Montcho C, Blanche S, Rouzioux C, Msellati P.

Pediatr Infect Dis J. 2005 Dec;24(12):1072-6.

PMID:
16371868
17.

Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.

Bergroth T, Ekici H, Gisslén M, Loes SK, Goh LE, Freedman A, Lampe F, Johnson MA, Sönnerborg A.

J Med Virol. 2009 Jan;81(1):1-8. doi: 10.1002/jmv.21363.

PMID:
19031460
18.

Low prevalence of drug-resistant HIV-1 in patients newly diagnosed with early stage of HIV infection in Korea.

Kim CO, Chin BS, Han SH, Lee HS, Jeong SJ, Choi HK, Choi JY, Song YG, Lee JS, Kim JM.

Tohoku J Exp Med. 2008 Nov;216(3):259-65.

19.

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.

Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL.

AIDS. 2006 Apr 4;20(6):863-70.

PMID:
16549970
20.

Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.

Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, Siberry GK, Spector SA.

Med Care. 2005 Sep;43(9 Suppl):III15-22.

PMID:
16116305
Items per page

Supplemental Content

Write to the Help Desk